September 23, 2024 |  This BioSpace article reviews the competitive pipeline in schizophrenia treatments, spotlighting five key candidates including Reviva Pharmaceuticals. The article highlights the potential impact of these emerging therapies to address the unmet needs in treating schizophrenia.

September 4, 2024 | Brian Kirkpatrick, MD and Mark Opler, PhD, MPH will discuss the unmet medical need and current treatment landscape for patients suffering from symptoms of schizophrenia, and application of speech latency as an objective vocal biomarker in schizophrenia clinical trials for evaluation of negative symptoms.

July 30, 2024 | In a recent article published in Nature Reviews Drug Discovery, Reviva CEO, Laxminarayan Bhat, comments on the effectiveness of muscarinic agonists in treating negative symptoms of schizophrenia. Dr. Bhat argues that these agonists, like D2-targeted drugs, primarily impact dopamine signaling and may only address positive symptoms. This insight underscores the ongoing unmet need for novel treatments that effectively target negative symptoms.

April 27, 2024 | HCPLive interview with Larry Ereshefsky, PharmD discussing other conditions brilaroxazine could potentially treat other than schizophrenia due to its mechanism.

April 24, 2024 | HCPLive interview with Larry Ereshefsky, PharmD discussing Reviva’s Phase 3 RECOVER trial which found brilaroxazine at 50 mg and 15 mg significantly reduced symptoms of acute schizophrenia and had a well-tolerated safety profile.

February 22, 2024 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Laxminarayan Bhat, Reviva CEO, discusses a number of subjects related to schizophrenia medication and treatment including treatment resistant patients, patent cliffs, pharma’s search for new products, options for commercialization and expected timeline for RECOVER 2.

February 22, 2024 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Laxminarayan Bhat, Reviva CEO, shares topline results and other findings from the Phase III RECOVER trial which evaluated brilaroxazine in schizophrenic patients.

February 22, 2024 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Laxminarayan Bhat, Reviva CEO, discusses the trial design for RECOVER 2 and some of the minor differences compares to RECOVER.

February 22, 2024 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Laxminarayan Bhat, Reviva CEO, examines recent M&A activity in the pharmaceutical sector, particularly within the CNS space.

February 22, 2024 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Laxminarayan Bhat, Reviva CEO, discusses some of the main findings from the completed Phase 3 RECOVER trial of brilaroxazine in schizophrenia .

February 22, 2024 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Laxminarayan Bhat, Reviva CEO, reviews biomarkers used evaluate brilaroxazine performance in the RECOVER trial including brain-derived neurotrophic factor (BDNF), markers of neuroinflammation and prolactin.

February 22, 2024 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Laxminarayan Bhat, Reviva CEO, shares primary findings of the Phase III RECOVER trial of Brilaroxazine in Schizophrenia.

February 15, 2024 | Larry Ereshefsky, PharmD, BCPP and Mark Opler, PhD, MPH discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine as a potential treatment. 

February 15, 2024 | Larry Ereshefsky, PharmD, BCPP and Mark Opler, PhD, MPH discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine as a potential treatment. 

October 30, 2023 | Reviva hosted a KOL Webinar to discuss the positive topline results and successful completion of its pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin-dopamine signaling modulator in adults with schizophrenia.

October 30, 2023 | Reviva hosted a KOL Webinar to discuss the positive topline results and successful completion of its pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin-dopamine signaling modulator in adults with schizophrenia.